Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female or male patients with at least 18 years at the time the informed consent is signed~2. ECOG performance status 0 or 1~3. Histological or cytological confirmed diagnostic of adenocarcinoma of the colon or rectum, with or without primary tumour in situ. Wild-type RAS and B-RAF tumor status.~4. Patients with potentially resectable metastatic disease at diagnosis and for whom a chemotherapy first in a curative intent is recommended . Resectability could be planed in one or multiple stage if indicated. As commonly admitted, resectability means the surgical clearance (+/- radiofrequency ablation) of all detectable (liver) lesions with tumor-free margins and compatible with an adequate hepatic reserve. Practically, bilateral tumor location, number and location of lesions, and inadequate hepatic reserve remain the main decisional factors.~5. Partial and minor resection of metastatic disease is allowed within 3 months before inclusion if patient has never received chemotherapy for mCRC.~6. Extra hepatic metastatic location is limited to 1 site.~7. Patients may have received adjuvant chemotherapy or (neo-) adjuvant chemo-radiotherapy to the pelvis, provided the last dose of chemotherapy was administered at least 6 months prior to inclusion (12 months for oxaliplatin). Previous radiotherapy to the pelvis is not an exclusion criterion.~8. Adequate haematological, renal and hepatic function as follows:~   Haematological:~   haemoglobin \>9g/dl Neutrophils \> 1.5 x 109/L Platelets \> 100 x 109/L~   Renal:~   Creatinine\< 1.5 x ULN (Upper Limit of Normal)~   Hepatic:~   Bilirubin \< or equal 1.5 X ULN AST (Aspartate Aminotransferase),and ALT (Alanine Aminotransferase)\< or equal 5 x ULN, Phos Alc\< or equal 5 x ULN~9. Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active using an acceptable method of contraception.~10. Male patients must be surgically sterile or if sexually active and having a pre-menopausal partner must be using an acceptable method of contraception.~11. Life expectancy of at least 3 months without any active treatment.~Exclusion Criteria:~* 1.Definitively non resectable mCRC at diagnosis~* 2.Prior chemotherapy or systemic therapy for mCRC. Adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months prior to inclusion. Oxaliplatin-based chemotherapy must be completed more than 1 year prior to inclusion.~* 3.Prior utilization of cetuximab, panitumumab (or other anti-EGFR (epidermal growth factor receptor)therapy).~* 4.Previous radiotherapy delivered to the upper abdomen.~* 5 Non mesurable disease( RECIST 1.1 criteria)~* 6.Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or thrombosis as determined by clinical or radiologic assessment.~* 7.Prior major liver resection: remnant liver \< 50% of the initial liver volume.~* 8.Non-malignant disease that would render the patient unsuitable for treatment according to this protocol.~* 9.Concurrent central nervous systems metastases~* 10.Peripheric neuropathy ≥ grade 2.~* 11.Interstitial lung disease~* 12.Pregnant or breast feeding.~* 13.The patient has previous or concomitant malignancies, except: Invasive malignancies in remission for more than 5 years and non melanoma skin cancer or carcinoma in situ of the cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oxaliplatin +leucovorin L+5FU+ cetuximab (Type: ACTIVE_COMPARATOR): oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
- Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab (Type: ACTIVE_COMPARATOR): Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues